Crafting Effective Summary Results Tables for Clinical Trial Registries

Importance of Summary Tables in Results Disclosure

Summary results tables are the foundation of data transparency on public clinical trial registries. These tables condense the trial’s key findings into structured, readable, and regulatory-compliant formats. Agencies like the FDA, EMA, and WHO require accurate tabular summaries for participant flow, baseline characteristics, outcomes, and adverse events.

Whether you are posting on ClinicalTrials.gov, EudraCT, or CTIS, proper table design ensures reviewers, patients, and regulators can interpret the study outcomes clearly. Poorly formatted or incomplete tables are a leading cause of Quality Control (QC) errors and result rejections.

Essential Table Types and What They Should Include

The four primary table categories common to most registries include:

• Participant Flow: Number of participants assigned, completed, or withdrawn at each phase.
• Baseline Characteristics: Demographic and clinical profile of the randomized population.
• Outcome Measures: Primary and secondary endpoint data with effect sizes and confidence intervals.
• Adverse Events: Summary of all reported adverse events, serious and non-serious, by arm.

Each table must be populated based on the analysis population defined in the statistical analysis plan (e.g., ITT or PP). The granularity required depends on the registry. CTIS and EudraCT support broader formats, while ClinicalTrials.gov enforces stricter structural and numerical rules through its PRS (Protocol Registration and Results System).

How to Structure a Baseline Characteristics Table

The baseline table helps readers determine whether the treatment groups were balanced before intervention. It must include:

• Age (mean ± SD or median + range)
• Sex (M/F counts and %)
• Disease duration or severity scale, if relevant
• Any other trial-specific covariates

Sample format:

Ensure that the totals match the number randomized in the participant flow table, as mismatches often trigger registry errors or flags.

Creating Effective Outcome Measure Tables

Outcome tables must show both statistical and clinical relevance. They typically include:

• Outcome label (e.g., “Change in Systolic Blood Pressure at Week 12”)
• Time point (Day, Week, Month)
• Value per group (Mean ± SD or Median + IQR)
• Between-group difference (if applicable)
• 95% Confidence Interval (CI)
• p-value (only if required by registry or protocol)

Tip: If results are unavailable at the time of posting, use “NA” but explain the reason in the free-text comment field of the registry.

Adverse Event Summary Table Formatting

Registries often require both all-cause and serious adverse event summaries. Adverse Event (AE) tables should follow standard MedDRA hierarchy or investigator terms. Include:

• Total number of participants experiencing ≥1 AE
• System organ class / Preferred term
• Severity (Mild, Moderate, Severe)
• Serious vs Non-serious status

Example Table:

Ensure AE totals reflect the safety population and align with source documents submitted to health authorities or used in the CSR.

Tools and Templates for Creating Tables

Several sponsors use predefined Excel templates to collate registry-compliant summary data. Tools such as:

• ClinicalTrials.gov PRS XML validator
• CTIS Module 5 format guidelines
• EudraCT Results QC checklist

can reduce formatting errors. Templates should include field-level instructions (e.g., decimal places, mandatory fields, allowable ranges) and be shared with all relevant stakeholders (Biostats, MW, QA).

For reusable templates, visit PharmaSOP.in.

Common Quality Control Failures and Fixes

Registry submissions often get flagged due to:

• Inconsistent participant numbers across tables
• Invalid statistical formats (e.g., CI without limits)
• Missing timepoints in outcome tables
• AE percentages exceeding 100%
• Unexplained “NA” entries

Before submission, perform a peer QC or use internal registry compliance tools. Annotated table maps that link to SAP and source data files are highly recommended.

Conclusion

Well-crafted summary tables not only fulfill a regulatory mandate but also build public and scientific trust. Consistency, traceability, and format accuracy are key to successful results posting. Training medical writers and data managers in these practices helps reduce delays and regulatory queries.

Explore more guidance on registry data formatting and transparency expectations at ICH.org.